Literature DB >> 10486263

Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxidase activation.

L A Rinckel1, S L Faris, N D Hitt, M E Kleinberg.   

Abstract

Phagocytic cells possess a tightly regulated multicomponent enzyme complex, the NADPH oxidase, which produces superoxide, a reactive oxygen molecule that is an essential component of host defense against infection. Upon stimulation, a functional NADPH oxidase is assembled when the cytosolic proteins, Rac, p67phox, p47phox, and possibly p40phox, associate with the gp91phox and p22phox transmembrane proteins. Rac is a GTPase that in the GTP-bound state binds p67phox to activate NADPH oxidase. The function of p40phox is not known; it is believed to have a regulatory function in sequestering p67phox and p47phox in a cytosolic complex. We investigated binding interactions between p40phox, p67phox, and Rac and found that Rac1-GTP displaced p67phox bound to p40phox. In contrast, Cdc42, a GTPase homologous to Rac, did not displace p67phox from p40phox. A synthetic peptide corresponding to p67phox amino acids 170-199, a region identified previously as a Rac binding domain, significantly reduced the ability of Rac1-GTP to disrupt p67phox/p40phox binding. We hypothesize that Rac-GTP binds the p67phox N-terminal domain encompassing amino acids 170-199 that transmits a conformational change which causes p40phox to dissociate from its binding site in the p67phox C-terminus. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486263     DOI: 10.1006/bbrc.1999.1334

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Role of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells.

Authors:  Jie Hong; Murray Resnick; Jose Behar; Jack Wands; Ronald A DeLellis; Weibiao Cao
Journal:  Am J Physiol Cell Physiol       Date:  2011-04-27       Impact factor: 4.249

2.  The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.

Authors:  Pascal Guerard; Zo Rakotoniaina; Françoise Goirand; Luc Rochette; Monique Dumas; Frederic Lirussi; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

Review 3.  Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment.

Authors:  Gianluca Tell; Damiano Fantini; Franco Quadrifoglio
Journal:  Cell Mol Life Sci       Date:  2010-08-13       Impact factor: 9.261

4.  The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Authors:  Zo Rakotoniaina; Pascal Guerard; Frederic Lirussi; Françoise Goirand; Luc Rochette; Monique Dumas; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-11       Impact factor: 3.000

5.  p40(phox) Participates in the activation of NADPH oxidase by increasing the affinity of p47(phox) for flavocytochrome b(558).

Authors:  A R Cross
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

6.  Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation.

Authors:  Andreas Goette; Alicja Bukowska; Christopher H Lillig; Uwe Lendeckel
Journal:  Front Physiol       Date:  2012-07-05       Impact factor: 4.566

7.  Potent Inhibitory Effect of BJ-3105, a 6-Alkoxypyridin-3-ol Derivative, on Murine Colitis Is Mediated by Activating AMPK and Inhibiting NOX.

Authors:  Pallavi Gurung; Sadan Dahal; Prakash Chaudhary; Diwakar Guragain; Ujjwala Karmacharya; Jung-Ae Kim; Byeong-Seon Jeong
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

8.  Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats.

Authors:  Jie Han; Dong-Mei Jiang; Yang Ye; Chang-Qing Du; Jian Yang; Shen-Jiang Hu
Journal:  Mol Med Rep       Date:  2016-03-21       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.